Tag: Cancer: Leukemia
Sitagliptin Promising Addition for Preventing Acute GVHD
Low incidence of grade II to IV acute GVHD seen in patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation
Oral Azacitidine Benefits Some Older Adults With AML
Overall, relapse-free survival prolonged among older patients in first remission after chemo who receive CC-486 versus placebo
Integrated Palliative and Oncology Care Improves QOL in Leukemia
Those receiving IPC were more likely to report discussing end-of-life preferences, were less likely to receive chemo at end of life
ASH: Stem Cell Transplant Benefits Older Adults With MDS
Overall survival, leukemia-free survival higher for patients assigned to allogeneic HCT versus those with no donor
ASH: Black Race Linked to Poorer Survival in AML
Among AML patients treated on Alliance protocols, Blacks versus Whites had inferior disease-free, overall survival
Predictors of Late Effects in Young AML Survivors Explored
Most common late effects were endocrine, cardiovascular, respiratory; likelihood of late effects up for those who underwent HSCT
Dasatinib + Blinatumomab Active for Ph-Positive ALL in Adults
Complete remission, overall survival seen in 98, 95 percent of patients in phase 2 study
Factors Associated With Suicide in Leukemia Identified
Risk factors include male sex, older age at diagnosis, White race
Measurable Residual Disease Negativity Tied to Survival in AML
AML patients without MRD have higher estimated rates of five-year disease-free, overall survival
Late Morbidity, Mortality Down for Survivors of Childhood ALL
Compared with 1970s, rate of subsequent malignant neoplasms lower with standard-risk 1990s-like therapy
